Sanofi Genzyme partners with Multiple Sclerosis Society of India

Mumbai: Sanofi Genzyme, the specialty care global business unit of Sanofi, and Multiple Sclerosis Society of India (MSSI) join hands to raise awareness and to provide better treatment solutions for the 130,000 people living with Multiple Sclerosis (MS) in India.

N. Rajaram, Managing Director, Sanofi India, said, ''At Sanofi, one of our priorities is to empower people with multiple sclerosis and improve their quality of life. Sanofi Genzyme is proud to support initiatives, including educational projects, and provide information and resources to raise awareness of multiple sclerosis in India. In line with that objective, we are in the process of introducing new and effective treatment options in India that would help in the management of this debilitating disease.''

Viresh Oberoi, Honorary President, Multiple Sclerosis Society of India (MSSI) said, ''During the month of May, every year, around the World, an added focus is brought to spread solidarity amongst our Members (those afflicted with multiple sclerosis, their caregivers and family members, doctors, nurses, well-wishers) and, to reach out to those who are not currently our Members to share with them how we can help them cope with this affliction. Even today we do not know with certainty what causes multiple sclerosis and how we can eliminate it. The theme of this year's 'celebration' of World MS Day is 'Bringing us closer - An objective, which I am sure which will make us all stronger and will provide hope for the future.''

Dr. P. Satishchandra, Senior Professor, Department of Neurology, National Institute of Mental Health and Neuro Sciences (NIMHANS), said, ''Today, with the advancement of technologies, we are better equipped to diagnose more cases of multiple sclerosis. Most people with MS have what is known as 'relapsing-remitting MS' where the relapse can be prevented with the use of appropriate disease modifying therapies. As a neurologist who treats many patients with MS, I wish to urge everyone to be more aware of the symptoms of this condition because an early diagnosis and appropriate treatment can ensure a healthier life.''

Sanofi Genzyme and MSSI are working together to ensure that people affected with multiple sclerosis can continue to live fuller lives through support programs that enhance their quality of life. The eight MSSI chapters in - Delhi, Mumbai, Bengaluru, Chennai, Hyderabad, Kolkata, Indore and Pune, along with Sanofi Genzyme are rolling out this year's campaign #bringinguscloser, through various awareness programs such as symposiums, MS camps, MS walks, medical seminars, photo exhibitions, and laughter & music therapy sessions.

These programs will help bring multiple sclerosis (MS) community together to share stories and raise awareness about the condition.

Sanofi Genzyme in India is focused on treatment for multiple sclerosis, rare diseases, and immunology. Through its partnership with the MSSI in India, Sanofi Genzyme is playing a critical role in enabling and empowering the lives of people with multiple sclerosis.

Globally, Sanofi Genzyme is continuously working to advance multiple sclerosis treatments and care with therapies, a portfolio of research and development-stage programs, and MS research collaborations.